Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|September 22, 2016
Metastatic Lung Cancer with Jared M. Weiss, MD: Case 1
Metastatic Lung Cancer with Jared M. Weiss, MD
Advertisement
Weiss case 1:
A 65-year-old man with stage IV NSCLC.
- Tissue biopsy showed EGFR+ adenocarcinoma
- The patient was enrolled in a clinical trial of erlotinib vs erlotinib/bevacizumab
- He was treated with erlotinib for 10 months before developing asymptomatic progression, with slowly growing lesions.
- He was continued on erlotinib for 3 more months; His next scan showed rapid progression.
- Repeat bronchoscopy and mutation testing showed an acquired EGFR T790M mutation
- Patient was subsequently switched to osimertinib
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5